218 related articles for article (PubMed ID: 18271849)
1. Effect of hepatitis C infection on anemia in hemodialysis patients.
Khurana A; Nickel AE; Narayanan M; Foulks CJ
Hemodial Int; 2008 Jan; 12(1):94-9. PubMed ID: 18271849
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
3. The influence of hepatitis C infection activity on oxidative stress markers and erythropoietin requirement in hemodialysis patients.
Tutal E; Sezer S; Ibis A; Bilgic A; Ozdemir N; Aldemir D; Haberal M
Transplant Proc; 2010 Jun; 42(5):1629-36. PubMed ID: 20620489
[TBL] [Abstract][Full Text] [Related]
4. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients.
Navarro JF; Teruel JL; Mateos M; Ortuño J
Clin Nephrol; 1994 Feb; 41(2):113-6. PubMed ID: 8004827
[TBL] [Abstract][Full Text] [Related]
7. Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients.
Ozdemir A; Yalinbaş B; Selamet U; Eres M; Murat B; Gürsu RU; Barut Y
Nephrology (Carlton); 2005 Oct; 10(5):433-7. PubMed ID: 16221090
[TBL] [Abstract][Full Text] [Related]
8. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
Chan K; Moran J; Hlatky M; Lafayette R
Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravenous iron therapy for HCV-positive haemodialysis patients.
Kahraman S; Yilmaz R; Genctoy G; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Nephron Clin Pract; 2005; 100(3):c78-85. PubMed ID: 15824511
[TBL] [Abstract][Full Text] [Related]
10. Oral iron absorption in hemodialysis patients treated with erythropoietin.
Donnelly SM; Posen GA; Ali MA
Clin Invest Med; 1991 Aug; 14(4):271-6. PubMed ID: 1782724
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076
[TBL] [Abstract][Full Text] [Related]
12. Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group.
Christophe JL; van Ypersele de Strihou C; Pirson Y
Nephrol Dial Transplant; 1996 Jul; 11(7):1271-6. PubMed ID: 8672022
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis.
Lemos LB; Perez RM; Matos CA; Silva IS; Silva AE; Ferraz ML
J Clin Gastroenterol; 2008 Feb; 42(2):208-11. PubMed ID: 18209594
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis status and mortality in hemodialysis population.
Santoro D; Mazzaglia G; Savica V; Li Vecchi M; Bellinghieri G
Ren Fail; 2009; 31(1):6-12. PubMed ID: 19142803
[TBL] [Abstract][Full Text] [Related]
15. [Helicobacter pylori does not contribute to iron deficiency in hemodialysis patients].
López T; Almirall J; Calvet X; Quesada M; Sanfeliú I; Segura F; García M
Nefrologia; 2006; 26(6):673-8. PubMed ID: 17227244
[TBL] [Abstract][Full Text] [Related]
16. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
Deaver K; Bennington L
Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
[TBL] [Abstract][Full Text] [Related]
17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
18. Determination of the impact of hepatitis C virus on insulin resistance and arterial stiffness in hemodialysis patients.
Adam FU; Torun D; Yigit F; Ozelsancak R; Sezer S; Ozdemir FN; Haberal M
Ren Fail; 2008; 30(4):411-5. PubMed ID: 18569915
[TBL] [Abstract][Full Text] [Related]
19. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients.
Sezer S; Tutal E; Bilgic A; Ozdemir FN; Haberal M
Transplant Proc; 2007; 39(1):40-4. PubMed ID: 17275471
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and severity of anemia in pediatric hemodialysis patients.
Azhir A; Nasiri J; Gheisari A
Saudi Med J; 2007 Feb; 28(2):249-53. PubMed ID: 17268705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
